CorMedix price target raised to $12 from $11 at RBC Capital

RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and logistical friction, along with favorable economics, the firm added.